Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-06

FDA Approved: TEPEZZA — Supplemental Application (Horizon Therapeutics USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TEPEZZA (teprotumumab) submitted by Horizon Therapeutics USA, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TEPEZZA (teprotumumab)

Snippet

SUPPL AP for TEPEZZA (TEPROTUMUMAB)